Tectonic Advisors LLC Secures 9,958 Shares in Gilead Sciences, Inc. (NASDAQ:GILD)

2 min read | October 25, 2024 04:45 AM PDT | By Team Kalkine Media

Google News:

Tectonic Advisors LLC Secures 9,958 Shares in Gilead Sciences, Inc. (NASDAQ:GILD) — Image source: Shutterstock

Recent News

Why Moderna Is Capturing Market Attention Again?

Eli Lilly Coverage Buzz Keeps Healthcare Market Attention High

Sandisk Gains Attention As an AI-Driven Growth Stock

Why Micron Technology Is Benefiting From the AI Growth Wave?

Make Kalkine Media
My Trusted Source

Highlights

Tectonic Advisors LLC increased its position in Gilead Sciences, Inc. by 15.1% during the third quarter.

Institutional ownership of Gilead has reached 83.67%, with several firms making notable adjustments to their stakes.

Analysts have raised their price projections for Gilead shares, reflecting a positive outlook on the company's performance.

Gilead Sciences, Inc. (NASDAQ:GILD) has recently seen significant activity among institutional investors, with Tectonic Advisors LLC expanding its stake by 15.1% in the third quarter, now holding 75,706 shares. This increase underscores growing confidence in the biopharmaceutical company. Institutional ownership in Gilead has risen to 83.67%, indicating strong institutional interest.

Other prominent institutions have also adjusted their holdings. Manning & Napier Advisors LLC established a new position valued at over $25 million during the second quarter. Legal & General Group Plc modestly raised its stake by 0.8%, acquiring an additional 93,068 shares, bringing its total to over 12 million shares. Additionally, firms like Wealth Enhancement Advisory Services LLC and Cetera Investment Advisers have also made substantial increases in their respective holdings, further highlighting the trend of institutional engagement with Gilead.

The price performance of Gilead shares has been notable, opening at $88.78 recently. The company boasts a market capitalization of approximately $110.61 billion, with a P/E ratio of 246.61. Gilead's stock has shown a twelve-month range with a low of $62.07 and a high of $89.21. The company reported robust quarterly earnings, exceeding consensus estimates with earnings per share of $2.01 and revenue of $6.95 billion.

Analysts have responded positively to Gilead's performance, with multiple firms raising their price projections. Needham & Company reaffirmed a "hold" rating, while Royal Bank of Canada increased its price projection from $74 to $75.00. Wells Fargo & Company raised its rating to "overweight" with a new price projection of $100. Collectively, Gilead Sciences has garnered a consensus rating of "Moderate Buy," suggesting optimism about its future performance in the biopharmaceutical sector.

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations and video (Content) is a service of Kalkine Media LLC (Kalkine Media, we or us) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media. Some of the images/music that may be used on this website are copyright to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.